One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
Price : 100$- Special Price : 50$
Guidance for JCO Authors on Subgroup Representation and Reporting.
doi : 10.1200/JCO-25-00803
Volume 43(25) pgs. 2759-2840,e59-e59 September 1, 2025
Long-Term (>=5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma.
doi : 10.1200/JCO-25-00760
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation.
doi : 10.1200/JCO-25-00856
Efficacy and Safety of Avutometinib +/- Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201.
doi : 10.1200/JCO-25-00112
Long-Term Follow-Up of Real-World Adjuvant Anti-PD-1 Checkpoint Inhibition and Targeted Therapy in Patients With Stage III Melanoma.
doi : 10.1200/JCO-24-02776
BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203.
doi : 10.1200/JCO-24-02595
Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non-Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy.
doi : 10.1200/JCO-24-02744
Totality of the Evidence: Optimizing Dosage Selection Strategies in Oncology.
doi : 10.1200/JCO-25-00488
Optimizing Allogeneic Chimeric Antigen Receptor T-Cell Persistence in Relapsed/Refractory Large B-Cell Lymphoma: The Role of KIR Matching.
doi : 10.1200/JCO-25-00394
Reply to: Optimizing Allogeneic Chimeric Antigen Receptor T-Cell Persistence in Relapsed/Refractory Large B-Cell Lymphoma: The Role of KIR Matching.
doi : 10.1200/JCO-25-00955
Reply to: Random Assignment, But Without Comparison: A Missed Opportunity.
doi : 10.1200/JCO-25-01271
Erratum: Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia.
doi : 10.1200/JCO-25-01631
Retraction: Disability-Adjusted Life Years From Human Papillomavirus-Related Oral Cavity and Pharynx Cancers in US Men, 2017-2021.
doi : 10.1200/JCO-25-01639
